ClinicalTrials.gg
CompletedNCT00164125Updated Feb 7, 2013

An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients

A Phase 4 interventional study of polyethyleneglycol3350 in Constipation, sponsored by Braintree Laboratories. Completed at 47 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-07.

Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.

Enrollment
Largest of 27
300 · median 100
Started
2003
with 2 others
Phase 4
16 of 27
2 open now
Registered
5th of 27
by date
Lead sponsor
7 of 27
Braintree Laboratories

Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one has the largest enrollment, is one of 3 that started in 2003, is one of 16 in phase 4, and was the 5th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About polyethylene glycol 3350

polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing polyethylene glycol 3350 in Constipation, or all of them as a file.
02

Study summary

To evaluate the safety of extended use of polyethyleneglycol3350 laxative in constipated patients.

03

Conditions studied

  • Constipation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • Male or female outpatients at least 18 years of age
  • Constipated according to ROME I criteria
  • If female and of , patient must be surgically sterilized or using oral , depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study
  • Are otherwise in good health, as judged by a physical examination
  • In the investigator's judgment, patient is mentally competent to sign an instrument of

Exclusion Criteria:

  • Patients with heme positive stool at screening. Patients with heme positive stool that can be attributed to hemorrhoids or anal fissures are eligible for inclusion.
  • Patients with hypo- or hyperthyroidism as determined by history, or screening TSH results.
  • Patients with known or suspected perforation or obstruction.
  • History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
  • Patients with a known history of organic cause for their constipation.
  • Patients meeting the ROME definition of Irritable Bowel Syndrome
  • Patients currently taking any of the following medications that are known to effect bowel habits:

    • Antidiarrheals
    • Antacids containing magnesium or aluminum salts
    • Anticholinergics
    • Antispasmodic agents
    • Erythromycin and other macrolides
    • Octreotide
    • Lotronex, Zofran, or other 5-HT3 antagonists
    • Zelnorm, or other 5-HT4 agonists
    • Opiods/narcotic analgesics
    • Prokinetics
    • Serotonin re-uptake inhibitors or tricyclic antidepressants
    • Calcium antagonists
  • Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
  • Female patients of childbearing potential who refuse a pregnancy test.
  • Patients with a known allergy to polyethyleneglycol.
  • Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Patients who, within the past 30 days have participated in an clinical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Safety (Adverse events and laboratory testing)

Secondary outcomes

  1. Assessment of constipation using ROME I criteria and analysis of individual ROME I criteria

07

Study locations

47 sites
  • Hoover, Alabama 35216, United States
  • Mobile, Alabama 36693, United States
  • Pell City, Alabama 35128, United States
  • Tallassee, Alabama 36078, United States
  • Glendale, Arizona 85306, United States
  • Phoenix, Arizona 85013, United States
  • Scottsdale, Arizona 85251, United States
  • Tucson, Arizona 85712, United States
  • Anaheim, California 92801, United States
  • Sacramento, California 95825, United States
  • Washington, District of Columbia 20037, United States
  • Kissimmee, Florida 34741, United States
  • Lake Worth, Florida 33461, United States
  • Largo, Florida 33770, United States
  • Ocoee, Florida 34761, United States
  • St. Petersburg, Florida 33702, United States
  • St. Petersburg, Florida 33707, United States
  • West Palm Beach, Florida 33407, United States
  • Atlanta, Georgia 30328, United States
  • Marietta, Georgia 30067, United States
  • Oakbrook Terrace, Illinois 60181, United States
  • Peoria, Illinois 61602, United States
  • Overland Park, Kansas 66215, United States
  • Laurel, Maryland 20707, United States
  • Springfield, Massachusetts 01107, United States
  • St. Louis, Missouri 63017, United States
  • South Bound Brook, New Jersey 08880, United States
  • Raleigh, North Carolina 27609, United States
  • Raleigh, North Carolina 27612, United States
  • Wilmington, North Carolina 28401, United States
  • Cincinnati, Ohio 45236, United States
  • Cincinnati, Ohio 45242, United States
  • Columbus, Ohio 43212, United States
  • Greer, South Carolina 29651, United States
  • Bristol, Tennessee 37620, United States
  • Kingsport, Tennessee 37660, United States
  • Memphis, Tennessee 38120, United States
  • Austin, Texas 78705, United States
  • Austin, Texas 78745, United States
  • Dallas, Texas 75231, United States
  • Fort Worth, Texas 76135, United States
  • San Angelo, Texas 76904, United States
  • Salt Lake City, Utah 84121, United States
  • Newport News, Virginia 23606, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23294, United States
  • Virginia Beach, Virginia 23454, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 14, 2005
Start
Jul 2003
Primary completionActual
Nov 2004
Last update
Feb 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00164125
First posted
Sep 14, 2005
Start date
Jul 2003
Primary completion
Nov 2004
Last update
Feb 7, 2013

Study contacts

Jorge Herrera, MD
principal investigator · University of South Alabama
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polyethylene glycol 3350

Start the discussion